Tobira Therapeutics

📍 South San Francisco, United States🗓 Founded 2007👥 3 employees💰 Last funded Aug 2010
Biotechnology🌐 tobiratherapeutics.com
Website LinkedIn
Tobira is focused on developing and commercializing innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV-1, fibrosis and inflammation. Its lead product candidate, cenicriviroc, or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. Tobira’s management team has extensive experience in developing and commercializing therapeutics for liver disease and HIV-1. The lead indication for CVC is non-alcoholic steatohepatitis, or NASH, for which Tobira plans to begin a Phase 2 clinical trial in the second half of 2014. The company believes there are no other product candidates in development for NASH that target the immuno-inflammatory pathways responsible for fibrosis. CVC also is Phase 3-ready in HIV-1 infection with potential as the backbone in a fixed-dose combination therapy. CVC is a once-daily pill with a safety and tolerability profile that has been established to date in 550 subjects dosed in completed Phase 1 and Phase 2 trials, including 115 HIV-1 infected subjects on treatment for up to 48 weeks.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2007
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Tobira Therapeutics?
Tobira Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Tobira Therapeutics last raise funding?
The most recent investment in Tobira Therapeutics recorded on gritt.io was in August 2010.
When was Tobira Therapeutics founded?
Tobira Therapeutics was founded in 2007.
What industry is Tobira Therapeutics in?
Tobira Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Tobira Therapeutics based?
Tobira Therapeutics is headquartered in South San Francisco, United States.